Management of Angiotensin Inhibitors During the Perioperative Period

NCT04506372 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 342

Last updated 2023-11-29

No results posted yet for this study

Summary

This is a multicenter randomized clinical trial to determine the effect of continuation versus withdrawal of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) in the perioperative period on postoperative complications.

Conditions

  • Surgery
  • Angiotensin Hypertension
  • Perioperative Complication

Interventions

DRUG

Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers

Withdrawal from 24 hours before surgery until 24-48 hours after surgery. The ACEI/ARB medication is resumed on the second or third day after surgery, as soon as the clinical condition allows based on judgement by the attending physician.

DIAGNOSTIC_TEST

Blood draw

Blood will be drawn to measure creatinin and troponin: once before surgery, on the first and second postoperative day, and within 4-8 weeks after surgery

BEHAVIORAL

Diary to register drug adherence

To register medication adherence, patients will be asked to fill out their medication intake (of ACEI/ARB) in a diary from a week before surgery until surgery.

BEHAVIORAL

Quality of life questionnaire

Patients are asked to fill out a quality of life questionnaire (EQ-5D) before surgery and at three months after surgery

BEHAVIORAL

WHODAS questionnaire

Patients are asked to fill out a questionnaire about disabilities (WHO Disability Assessment Schedule 2.0) before surgery and at three months after surgery

Sponsors & Collaborators

  • ZonMw: The Netherlands Organisation for Health Research and Development

    collaborator OTHER
  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Judith van Waes, MD PhD · UMC Utrecht

  • Wilton van Klei, MD PhD · UMC Utrecht

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-11
Primary Completion
2023-02-06
Completion
2023-09-01

Countries

  • Canada
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04506372 on ClinicalTrials.gov